http://rdf.ncbi.nlm.nih.gov/pubchem/patent/MX-PA00010110-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a41ef2cd52971eb41bc0a50557b590c8 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1647 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0024 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-127 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-18 |
| filingDate | 1999-04-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_40411fc6fb34e8aec22923a7763e657b |
| publicationDate | 2002-08-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | MX-PA00010110-A |
| titleOfInvention | THERAPEUTIC ANGIOGENIC FACTORS AND METHODS FOR USE. |
| abstract | Methods are provided to stimulate angiogenesis in a human or animal in need thereof. Compositions comprising an angiogenic factor in a pharmaceutically acceptable carrier are also provided. In another aspect, the method comprises administering to the human or animal a therapeutically effective amount of an angiogenic factor, such as a pleiotrophin or midkin protein, in a pharmaceutically acceptable carrier. The carrier in one aspect comprises a controlled release matrix, such as a polymer that allows to control the release of the angionic factor. The polymer may be biodegradable, and / or bioerodible and preferably biocompatible. Polymers which can be used to control release include, for example, poly (esters), poly (anhydrides), and poly (amino acids). Exemplary polymers include poly (amino acid) elastin silk block copolymers and polylactide-co-glycolide. The carrier, such as a liposome, can be provided with an indicator ligand capable of directing the carrier to a preselected site in the body. The angiogenic factor can be administered to the vascular system, for example to the cardiovascular system, or to the peripheral vascular system. In a preferred aspect, the angiogenic factor is a pleiotrophin protein, or a midkin protein. In another aspect, a method is provided to stimulate angiogenesis in a human or animal comprising the administration of a therapeutically effective amount of a vector, transferring the gene that encodes the production of the pleiotrophin or midkin protein in a pharmaceutically acceptable carrier. The gene transfer vector can be, for example, pure DNA or a viric vector, and can be administered, for example, in combination with liposomes. |
| priorityDate | 1998-04-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 268.